June 29, 2018 — Embolx Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation family of Sniper Balloon Occlusion Microcatheters for pressure-directed arterial embolization therapy. Now commercially available in the United States, the next-generation family of Sniper devices offers physicians enhanced performance features to improve access and allow easy navigation through small complex vascular structures.

Embolx’s next-generation Sniper microcatheter is now available in three lengths – 110, 130 and 150 cm – now enabling interventional radiologist physicians to access either femoral or radial arterial sites. Advancements in the Sniper’s balloon and atraumatic tip designs allow larger vessels to be occluded and enhance the ability for Sniper to track inside vessels.

The Sniper microcatheter alters blood flow‐dynamics by controlling pressure to increase therapeutic agent delivery into target areas. It is currently used for the treatment of cancerous tumors in the liver and other organs, enlarged prostate (also called benign prostatic hyperplasia) and uterine fibroids. This therapy allows the delivery of drugs and embolic agents to only targeted treatment areas, while protecting surrounding healthy tissues.

"The great thing about Sniper's enhanced design and longer lengths is that it allows me to perform procedures using a transradial approach with the benefits of pressure-directed embolization. The ability to reverse blood flow using Sniper's balloon helps me to not have to worry about non-target embolization," said Aaron M. Fischman, M.D., interventional radiologist and associate professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai. "I can perform the procedure the way I want because of Sniper's wide range compatibility with different guidewires, guide catheters, coils and therapeutic agents."

Embolization is a minimally invasive procedure performed by interventional radiologists where blood supply to organs or tumors are blocked after therapeutic agents are injected in a blood vessel near the treatment location.